Analysts predict that Insmed, Inc. (NASDAQ:INSM) will announce earnings per share (EPS) of ($0.81) for the current quarter, Zacks reports. Zero analysts have made estimates for Insmed’s earnings. The lowest EPS estimate is ($1.03) and the highest is ($0.26). Insmed reported earnings of ($0.60) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 35%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, May 2nd.
According to Zacks, analysts expect that Insmed will report full-year earnings of ($3.80) per share for the current fiscal year, with EPS estimates ranging from ($4.32) to ($3.24). For the next year, analysts forecast that the company will post earnings of ($2.86) per share, with EPS estimates ranging from ($3.94) to ($2.04). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Insmed.
Insmed (NASDAQ:INSM) last announced its earnings results on Friday, February 23rd. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.18).
INSM has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Insmed in a report on Thursday, January 4th. Morgan Stanley began coverage on Insmed in a research note on Wednesday, March 21st. They set an “overweight” rating and a $39.00 price target on the stock. Robert W. Baird reissued a “positive” rating and set a $42.00 price target (up previously from $32.00) on shares of Insmed in a research note on Thursday, January 4th. BidaskClub lowered Insmed from a “hold” rating to a “sell” rating in a research note on Tuesday, March 20th. Finally, Zacks Investment Research lowered Insmed from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $36.90.
Shares of NASDAQ:INSM traded up $0.06 during trading on Tuesday, reaching $20.06. 952,610 shares of the company traded hands, compared to its average volume of 724,370. The firm has a market cap of $1,536.96, a PE ratio of -6.94 and a beta of 1.11. Insmed has a 52-week low of $11.49 and a 52-week high of $33.94. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.72 and a current ratio of 8.72.
Several hedge funds and other institutional investors have recently modified their holdings of INSM. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Insmed by 137.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,662 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 2,698 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in shares of Insmed in the fourth quarter valued at approximately $188,000. Prudential Financial Inc. acquired a new stake in shares of Insmed in the third quarter valued at approximately $232,000. Jefferies Group LLC acquired a new stake in shares of Insmed in the fourth quarter valued at approximately $245,000. Finally, Xact Kapitalforvaltning AB acquired a new stake in shares of Insmed in the fourth quarter valued at approximately $258,000. 99.08% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/zacks-brokerages-anticipate-insmed-inc-insm-to-post-0-81-eps.html.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Get a free copy of the Zacks research report on Insmed (INSM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.